| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/01.HYP.25.6.1345 |
| P698 | PubMed publication ID | 7768585 |
| P2093 | author name string | C S Sweet | |
| D B Snavely | |||
| E B Nelson | |||
| A I Goldberg | |||
| A H Gradman | |||
| K E Arcuri | |||
| L S Ikeda | |||
| P433 | issue | 6 | |
| P921 | main subject | placebo | Q269829 |
| losartan | Q410074 | ||
| enalapril | Q422185 | ||
| essential hypertension | Q988405 | ||
| P304 | page(s) | 1345-1350 | |
| P577 | publication date | 1995-06-01 | |
| P1433 | published in | Hypertension | Q5958695 |
| P1476 | title | A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension | |
| P478 | volume | 25 |
| Q44034800 | A comparison of candesartan, felodipine, and their combination in the treatment of elderly patients with systolic hypertension |
| Q74618286 | A multicenter, randomized, double-blind, placebo-controlled, 8-week trial of the efficacy and tolerability of once-daily losartan 100 mg/hydrochlorothiazide 25 mg and losartan 50 mg/hydrochlorothiazide 12.5 mg in the treatment of moderate-to-severe |
| Q28543493 | A randomized, double blind, placebo-controlled, multicenter phase II trial of Allisartan Isoproxil in essential hypertensive population at low-medium risk |
| Q40915483 | A risk-benefit assessment of losartan potassium in the treatment of hypertension |
| Q41156671 | ACE inhibitor-induced cough and bronchospasm. Incidence, mechanisms and management |
| Q34761145 | AT(1)-receptor blockers: differences that matter |
| Q43004586 | Amelioration of 2,4,6-trinitrobenzene sulphonic acid induced colitis in angiotensinogen gene knockout mice |
| Q47849943 | An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan. Irbesartan/Losartan Study Investigators |
| Q73357670 | An improved method for the simultaneous determination of losartan and its major metabolite, EXP3174, in human plasma and urine by high-performance liquid chromatography with fluorescence detection |
| Q71697836 | An inpatient trial of the safety and efficacy of losartan compared with placebo and enalapril in patients with essential hypertension |
| Q33851581 | Angiotensin II receptor antagonists |
| Q40892935 | Angiotensin II receptor antagonists. Potential in elderly patients with cardiovascular disease |
| Q41311382 | Angiotensin-II-receptors: new targets for antihypertensive therapy |
| Q41495127 | Angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists and calcium channel blocking agents: a review of potential benefits and possible adverse reactions |
| Q64907215 | Assessment of once-daily eprosartan, an angiotensin II antagonist, in patients with systemic hypertension. Eprosartan Study Group. |
| Q24240794 | Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension |
| Q24240959 | Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension |
| Q44641054 | Central and peripheral hemodynamic effects of losartan and in combination with hydrochlorothiazide in mild to moderate essential hypertension |
| Q47913024 | Clinical pharmacokinetics of vasodilators. Part I. |
| Q44280775 | Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial |
| Q74060342 | Comparison of three blood pressure measurement methods for the evaluation of two antihypertensive drugs: feasibility, agreement, and reproducibility of blood pressure response |
| Q35016775 | Comprehensive overview: efficacy, tolerability, and cost-effectiveness of irbesartan |
| Q87872242 | Differences Among Angiotensin II Type 1 Receptor Blockers: Characteristics of Candesartan Cilexetil |
| Q45054579 | Disparate systemic and renal blocking properties of angiotensin II antagonists during exogenous angiotensin II administration: implications for treatment |
| Q77899300 | Dose-responsive antihypertensive efficacy of valsartan, a new angiotensin II-receptor blocker |
| Q40850718 | Drug discovery: past, present and future. |
| Q71378091 | Effects of cimetidine on pharmacokinetics and pharmacodynamics of losartan, an AT1-selective non-peptide angiotensin II receptor antagonist |
| Q34659473 | Efficacy of angiotensin II receptor antagonists in preventing headache: a systematic overview and meta-analysis |
| Q53620961 | Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension. |
| Q53623646 | Efficacy, tolerability, and quality of life of losartan, alone or with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension. |
| Q42781225 | Endogenous angiotensin II and baroreceptor dysfunction: a comparative study of losartan and enalapril in man. |
| Q87872251 | Improving Antihypertensive Efficacy while Maintaining Placebo-like Tolerability |
| Q43796478 | Irbesartan, an angiotensin type 1 receptor inhibitor, regulates the vascular oxidative state in patients with coronary artery disease |
| Q33788387 | Long-term benefits of angiotensin II blockade: is the consensus changing? |
| Q40940040 | Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension |
| Q30660658 | Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trial |
| Q54029918 | Losartan, an angiotensin type 1 receptor antagonist, improves endothelial function in non-insulin-dependent diabetes. |
| Q41615112 | Losartan, an orally active angiotensin (AT1) receptor antagonist: a review of its efficacy and safety in essential hypertension |
| Q41857937 | Modulation of haemodynamics, endogeneous antioxidant enzymes, and pathophysiological changes by selective inhibition of angiotensin II type 1 receptors in pressureoverload rats |
| Q41333137 | Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonists. |
| Q44633207 | Prostacyclin and thromboxane A2 production in nitric oxide-deficient hypertension in vivo. Effects of high calcium diet and angiotensin receptor blockade |
| Q71771578 | Rationale, background, and design of the randomized angiotensin receptor antagonist--angiotensin-converting enzyme inhibitor study (RAAS) |
| Q56832849 | Reversible ageusia associated with losartan |
| Q93346207 | Sex-specific long-term blood pressure regulation: Modeling and analysis |
| Q44567348 | Simultaneous determination of losartan and EXP3174 in human plasma and urine utilizing liquid chromatography/tandem mass spectrometry |
| Q35802524 | Start of therapy with the angiotensin II antagonist losartan after immediate switch from pretreatment with an ACE inhibitor |
| Q41321509 | The angiotensin II type 1 receptor blocker losartan in clinical practice: a review |
| Q43631503 | Tolerability of antihypertensive drugs in a community-based setting |
| Q73507586 | [Do angiotensin II receptor antagonists substitute angiotensin converting enzyme inhibitors in the treatment of high blood pressure?] |
Search more.